Palonosetron as an anti-emetic and anti-nausea agent in oncology

por Aapro, Matti S
Publicado 2007

SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly

por Aapro, Matti
Publicado 2011

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts

por Aapro, Matti
Publicado 2018

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction

por Aapro, Matti
Publicado 2018

CINV: still troubling patients after all these years

por Aapro, Matti
Publicado 2018

The Role of Multigene Assays in Addressing Treatment Heterogeneity for Breast Cancer

por Aapro, Matti
Publicado 2017

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?

por Aapro, Matti, Crawford, Jeffrey, Kamioner, Didier
Publicado 2010

Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases

por Aapro, Matti, Saad, Fred, Costa, Luis
Publicado 2010

From guidelines to clinical practice: a roadmap for oncologists for nutrition therapy for cancer patients

por Muscaritoli, Maurizio, Arends, Jann, Aapro, Matti
Publicado 2019

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy

por Zelek, Laurent, Navari, Rudolph, Aapro, Matti, Scotté, Florian
Publicado 2023

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained

por Aapro, Matti, Krendyukov, Andriy, Schiestl, Martin, Gascón, Pere
Publicado 2018

Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era

por Lyman, Gary H., Kuderer, Nicole M., Aapro, Matti
Publicado 2021

Treatment patterns and outcomes in patients with non‐small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy‐induced/febrile neutropaenia: Results fr...

por Aapro, Matti, Krendyukov, Andriy, Höbel, Nadja, Gascon, Pere
Publicado 2019

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?

por Boccia, Ralph, Glaspy, John, Crawford, Jeffrey, Aapro, Matti
Publicado 2022

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)

por Baron-Hay, Sally, Aapro, Matti, Bernareggi, Alberto, Schwartzberg, Lee
Publicado 2019

Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure

por Cornes, Paul, Gascon, Pere, Vulto, Arnold G., Aapro, Matti
Publicado 2020

Development and 10-year history of a biosimilar: the example of Binocrit(®)

por Aapro, Matti, Krendyukov, Andriy, Höbel, Nadja, Seidl, Andreas, Gascón, Pere
Publicado 2018

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim

por Gascon, Pere, Krendyukov, Andriy, Mathieson, Nicola, Natek, Maja, Aapro, Matti
Publicado 2019

Oncologist perspectives on chemotherapy‐induced nausea and vomiting (CINV) management and outcomes: A quantitative market research‐based survey

por Aapro, Matti, Ruffo, Pierfrancesco, Panteri, Roger, Costa, Stefano, Piovesana, Vittoria
Publicado 2018

Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the r...

por Celio, Luigi, Bonizzoni, Erminio, De Braud, Filippo, Agustoni, Francesco, Aapro, Matti
Publicado 2015